Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Terns Pharmaceuticals (TERN) Enterprise Value (2021 - 2026)

Terns Pharmaceuticals filings provide 6 years of Enterprise Value readings, the most recent being -$995.0 million for Q4 2025.

  • Quarterly Enterprise Value fell 177.81% to -$995.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$995.0 million through Dec 2025, down 177.81% year-over-year, with the annual reading at -$995.0 million for FY2025, 177.81% down from the prior year.
  • Enterprise Value hit -$995.0 million in Q4 2025 for Terns Pharmaceuticals, down from -$271.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$139.8 million in Q2 2022 and bottomed at -$995.0 million in Q4 2025.
  • Average Enterprise Value over 5 years is -$271.3 million, with a median of -$245.8 million recorded in 2024.
  • The largest annual shift saw Enterprise Value plummeted 1572.2% in 2021 before it increased 24.46% in 2022.
  • Terns Pharmaceuticals' Enterprise Value stood at -$166.0 million in 2021, then rose by 1.85% to -$162.9 million in 2022, then crashed by 61.71% to -$263.4 million in 2023, then crashed by 35.96% to -$358.2 million in 2024, then tumbled by 177.81% to -$995.0 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Enterprise Value are -$995.0 million (Q4 2025), -$271.5 million (Q3 2025), and -$315.4 million (Q2 2025).